12:00 AM
 | 
May 08, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Targretin bexarotene capsules: Phase II data; Marketed to treat refractory cutaneous T cell lymphoma (CTCL)

LGND presented interim data from 3 of 4 dosage groups in its 37-patient European Phase II trial (see BioCentury, June 28, 1999). In the 3 groups (0.5-2 mg/kg/day), up to 50 percent of patients had a two-grade improvement in...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >